首页> 外文期刊>Nature >Suppression of lung adenocarcinoma progression by Nkx2-1
【24h】

Suppression of lung adenocarcinoma progression by Nkx2-1

机译:Nkx2-1抑制肺腺癌进展

获取原文
获取原文并翻译 | 示例
       

摘要

Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS' and inactivation of the p53 pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras~(LSL-G12D/+);p53~(flox/flox) mice initiates lung adenocarcinoma development4. Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain- and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.
机译:尽管转移性肺癌患者的高患病率和不良预后,但肿瘤进展和转移的机制仍未明确。在这里,我们建立了人类肺腺癌的模型,该腺癌经常在小鼠中使用条件等位基因,在KRAS'中具有激活点突变和p53途径失活。慢病毒介导的Kras〜(LSL-G12D / +); p53〜(flox / flox)小鼠肺上皮细胞的体细胞激活致癌性Kras和p53缺失启动了肺腺癌的发展4。尽管肿瘤是由确定的遗传改变同步引发的,但只有一部分会变成恶性肿瘤,这表明疾病的进展需要其他改变。慢病毒整合位点的鉴定使我们能够区分转移性肿瘤与非转移性肿瘤,并确定区分这些肿瘤类型的基因表达变化。跨物种分析确定了与NK2相关的同源盒转录因子Nkx2-1(也称为Ttf-1或Titf1)是恶性进展的候选抑制剂。在此小鼠模型中,Nkx2-1阴性是高级低分化肿瘤的病理特征。在源自转移性和非转移性肿瘤的细胞中的功能获得和丧失功能实验表明,Nkx2-1控制肿瘤分化并限制体内转移潜能。对Nkx2-1调节基因的询问,在确定的发育阶段进行的肿瘤分析以及功能互补实验表明,Nkx2-1通过抑制受胚胎限制的染色质调节剂Hmga2来部分限制肿瘤。尽管在部分人肺腺癌中NKX2-1的局灶扩增已将注意力集中在其致癌功能上,但我们的数据明确地将Nkx2-1的下调与分化的丧失,增强的肿瘤播种能力和增加的转移倾向联系起来。因此,在相同肿瘤类型中,Nkx2-1的致癌和抑制功能证实了其作为双重功能谱系因子的作用。

著录项

  • 来源
    《Nature》 |2011年第7345期|p.101-104|共4页
  • 作者单位

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA,LudwigCenter for Molecular Oncology, Massachusetts Institute of Technology,Cambridge, Massachusetts 02139, USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    Dana-Farber Cancer Institute, Harvard University, Cambridge, Massachusetts 02115, USA,Broad Institute,Cambridge, Massachusetts 02142,USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA,LudwigCenter for Molecular Oncology, Massachusetts Institute of Technology,Cambridge, Massachusetts 02139, USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    Dana-Farber Cancer Institute, Harvard University, Cambridge, Massachusetts 02115, USA,Broad Institute,Cambridge, Massachusetts 02142,USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA;

    Department of Biomedical Sciences, Tufts University Veterinary School, North Grafton, Massachusetts 01536, USA;

    Dana-Farber Cancer Institute, Harvard University, Cambridge, Massachusetts 02115, USA,Broad Institute,Cambridge, Massachusetts 02142,USA,Department of Genetics, University of North Carolina, North Carolina 27599, USA;

    Dana-Farber Cancer Institute, Harvard University, Cambridge, Massachusetts 02115, USA,Broad Institute,Cambridge, Massachusetts 02142,USA;

    David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA,LudwigCenter for Molecular Oncology, Massachusetts Institute of Technology,Cambridge, Massachusetts 02139, USA,Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA,Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge,Massachusetts 02139, USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:33

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号